<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="pmc-domain-id">1526</journal-id><journal-id journal-id-type="pmc-domain">frontmicrobio</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9271922</article-id><article-id pub-id-type="pmcid-ver">PMC9271922.1</article-id><article-id pub-id-type="pmcaid">9271922</article-id><article-id pub-id-type="pmcaiid">9271922</article-id><article-id pub-id-type="pmid">35832809</article-id><article-id pub-id-type="doi">10.3389/fmicb.2022.948770</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Dai</surname><given-names initials="J">Jiayu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1753346/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Yibo</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn002" ref-type="author-notes">
<sup>&#8224;</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1753345/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="H">Hongrui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1860603/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gao</surname><given-names initials="Z">Ziyuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1860602/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="Y">Ying</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1860604/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fang</surname><given-names initials="M">Mingli</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/784265/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shi</surname><given-names initials="S">Shuyou</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1860619/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhang</surname><given-names initials="P">Peng</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="H">Hua</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1842892/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Su</surname><given-names initials="Y">Yingying</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1861270/overview"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Yang</surname><given-names initials="M">Ming</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c002" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1824827/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Molecular Biology, College of Basic Medical Sciences, Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>College of Clinical Medicine, Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Thoracic Surgery, The First Affiliated Hospital of Jilin University</institution>, <addr-line>Changchun</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>Department of Anatomy, College of Basic Medical Sciences, Jilin University</institution>, <addr-line>Jilin</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Na Li, Hainan Medical University, China</p></fn><fn fn-type="edited-by"><p>Reviewed by: Pan Liu, Northwestern University, United States; Guopeng Wang, Peking University, China</p></fn><corresp id="c001">*Correspondence: Yingying Su, <email>suyingying@jlu.edu.cn</email></corresp><corresp id="c002">Ming Yang, <email>myang48@jlu.edu.cn</email></corresp><fn fn-type="equal" id="fn002"><p><sup>&#8224;</sup>These authors have contributed equally to this work</p></fn><fn fn-type="other" id="fn004"><p>This article was submitted to Infectious Agents and Disease, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>27</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>13</volume><issue-id pub-id-type="pmc-issue-id">400063</issue-id><elocation-id>948770</elocation-id><history><date date-type="received"><day>20</day><month>5</month><year>2022</year></date><date date-type="accepted"><day>06</day><month>6</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>27</day><month>06</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>12</day><month>07</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-07-04 15:25:15.520"><day>04</day><month>07</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Dai, Wang, Wang, Gao, Wang, Fang, Shi, Zhang, Wang, Su and Yang.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Dai, Wang, Wang, Gao, Wang, Fang, Shi, Zhang, Wang, Su and Yang</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fmicb-13-948770.pdf"/><abstract><p>Toll-like receptors (TLRs) are key sensors that recognize the pathogen-associated molecular patterns (PAMPs) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to activate innate immune response to clear the invading virus. However, dysregulated immune responses may elicit the overproduction of proinflammatory cytokines and chemokines, resulting in the enhancement of immune-mediated pathology. Therefore, a proper understanding of the interaction between SARS-CoV-2 and TLR-induced immune responses is very important for the development of effective preventive and therapeutic strategies. In this review, we discuss the recognition of SARS-CoV-2 components by TLRs and the downstream signaling pathways that are activated, as well as the dual role of TLRs in regulating antiviral effects and excessive inflammatory responses in patients with coronavirus disease 2019 (COVID-19). In addition, this article describes recent progress in the development of TLR immunomodulators including the agonists and antagonists, as vaccine adjuvants or agents used to treat hyperinflammatory responses during SARS-CoV-2 infection.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>innate immune response</kwd><kwd>Toll-like receptor</kwd><kwd>immunomodulator</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Department of Finance of Jilin Province</institution><institution-id institution-id-type="doi">10.13039/501100009991</institution-id></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source id="cn002"><institution-wrap><institution>National Natural Science Foundation of China</institution><institution-id institution-id-type="doi">10.13039/501100001809</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><equation-count count="0"/><ref-count count="92"/><page-count count="11"/><word-count count="8630"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="S1"><title>Introduction</title><p>Toll-like receptors (TLRs) are members of the pattern recognition receptor (PRR) family, and they play pivotal roles in the activation of innate immune responses and the regulation of cytokine expression (<xref rid="B29" ref-type="bibr">Hedayat et al., 2011</xref>; <xref rid="B6" ref-type="bibr">Birra et al., 2020</xref>; <xref rid="B17" ref-type="bibr">Debnath et al., 2020</xref>). TLRs perform their functions by recognizing distinguishing molecules of invading pathogens, called pathogen-associated molecular patterns (PAMPs), and then initiate innate immune responses <italic toggle="yes">via</italic> several distinct signaling pathways, thereby limiting infection and promoting adaptive immune responses (<xref rid="B35" ref-type="bibr">Kawai and Akira, 2011</xref>). Generally, myeloid differentiation primary response 88 (MyD88) and Toll-IL-1R (TIR)-domain containing adaptor-inducing interferon-&#946; (TRIF) are the two main pathways by which TLRs transduce signals after activation (<xref rid="B42" ref-type="bibr">Kim et al., 2018</xref>).</p><p>The innate immune system acts as the first line of defense against invading pathogens, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative viral pathogen of the coronavirus disease 2019 (COVID-19), and the COVID-19 pandemic began in March 2020 (<xref rid="B72" ref-type="bibr">Tabary et al., 2020</xref>). The characteristics of COVID-19 are extremely variable, and the disease ranges from an asymptomatic form lasting for a few days or mild to severe forms of interstitial pneumonia which requires ventilation therapy and can lead to death (<xref rid="B41" ref-type="bibr">Khan et al., 2020</xref>). TLRs recognize SARS-CoV-2-derived molecules and activate innate immune responses. Many studies have shown that SARS-CoV-2 activates the innate immune system <italic toggle="yes">via</italic> TLRs, and mediates the upregulation of TLR expression, which contribute to the elimination of the virus (<xref rid="B1" ref-type="bibr">Aboudounya and Heads, 2021</xref>; <xref rid="B8" ref-type="bibr">Bortolotti et al., 2021</xref>; <xref rid="B65" ref-type="bibr">Sariol and Perlman, 2021</xref>). However, TLR activation may act as a double-edged sword, and dysregulated TLR responses may lead to persistent inflammation and tissue destruction (<xref rid="B87" ref-type="bibr">Yokota et al., 2010</xref>; <xref rid="B18" ref-type="bibr">Ebermeyer et al., 2021</xref>). For instance, the severity of COVID-19 is associated with cytokine storms in patients which could be produced by overactivation of TLR pathways (<xref rid="B73" ref-type="bibr">Tang et al., 2020</xref>; <xref rid="B50" ref-type="bibr">Manik and Singh, 2021</xref>). Therefore, a better understanding of the relationship between TLRs and SARS-CoV-2 is critical for understanding the immunopathogenesis involved in COVID-19 and for the preventive and therapeutic application of TLR immunomodulators to combat the disease. In this review, we provide an overview of our recent understanding of the roles of TLRs in SARS-CoV-2-induced immune responses, and we discuss the potential prophylactic and/or therapeutic value of TLR agonists or antagonists in COVID-19 patients.</p></sec><sec id="S2"><title>Structure and Classification of Toll-Like Receptors</title><p>All TLRs are type I transmembrane proteins that consist of a leucine-rich repeat (LRR) module, a transmembrane region, and a TIR domain. The LRR motif includes 19&#8211;25 tandem sequences containing leucine and is responsible for the recognition of PAMPs, while the TIR endodomain functions to initiate intracellular signaling events <italic toggle="yes">via</italic> downstream adaptors. According to the composition of their subunits, TLRs operate as heterodimers or homodimers. The classification and expression of TLRs differs between species. Thirteen TLRs have been discovered in mice. However, TLR11 has no function, and the TLR12 and TLR13 genes are absent in the human genome. Generally, the TLR family can be divided into two subgroups based on their localization: cell surface TLRs and intracellular TLRs (<xref rid="B36" ref-type="bibr">Kawasaki and Kawai, 2014</xref>). Cell surface TLRs reside on the cell membrane and mainly contain TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10, while intracellular TLRs include TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13 (<xref rid="T1" ref-type="table">Table 1</xref>). Intracellular TLRs localize to intracellular compartments, such as the endosomes, endoplasmic reticulum, and lysosomes.</p><table-wrap position="float" id="T1" orientation="portrait"><label>TABLE 1</label><caption><p>Human and murine TLR classification and their natural ligands.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">Classification</td><td valign="top" align="left" rowspan="1" colspan="1">TLR name</td><td valign="top" align="left" rowspan="1" colspan="1">Gene location</td><td valign="top" align="left" rowspan="1" colspan="1">Ligands</td><td valign="top" align="left" rowspan="1" colspan="1">References</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Cell surface TLRs</td><td valign="top" align="left" rowspan="1" colspan="1">TLR1</td><td valign="top" align="left" rowspan="1" colspan="1">5C3.1 (mouse)/4p14 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">Triacylated lipopeptides, lipoarabinomannan</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B88" ref-type="bibr">Yu and Feng, 2018</xref>; <xref rid="B69" ref-type="bibr">Su et al., 2019</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR2</td><td valign="top" align="left" rowspan="1" colspan="1">3E3 (mouse)/4q31.3 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">Zymosan, peptidoglycan, lipoteichoic acid, endogenous HSP, HMGB1, gp96</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B57" ref-type="bibr">Patidar et al., 2018</xref>; <xref rid="B88" ref-type="bibr">Yu and Feng, 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR4</td><td valign="top" align="left" rowspan="1" colspan="1">4C1 (mouse)/9q33.1 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">LPS, endogenous HSP, HMGB1, &#946;-defensin 2</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B78" ref-type="bibr">Vaure and Liu, 2014</xref>; <xref rid="B57" ref-type="bibr">Patidar et al., 2018</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR5</td><td valign="top" align="left" rowspan="1" colspan="1">1H5 (mouse)/1q41 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">Flagellin</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B86" ref-type="bibr">Yang and Yan, 2017</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR6</td><td valign="top" align="left" rowspan="1" colspan="1">5C3.1 (mouse)/4p14 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">Diacylated lipopeptides, zymosan, lipoteichoic acid</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B88" ref-type="bibr">Yu and Feng, 2018</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR10</td><td valign="top" align="left" rowspan="1" colspan="1">4p14 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">Unknown</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B36" ref-type="bibr">Kawasaki and Kawai, 2014</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intracellular TLRs</td><td valign="top" align="left" rowspan="1" colspan="1">TLR3</td><td valign="top" align="left" rowspan="1" colspan="1">8B1.1 (mouse)/4q35.1 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">dsRNA</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B77" ref-type="bibr">Turton et al., 2020</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR7</td><td valign="top" align="left" rowspan="1" colspan="1">XF5 (mouse)/Xp22.2 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">ssRNA</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B74" ref-type="bibr">Tanji et al., 2013</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR8</td><td valign="top" align="left" rowspan="1" colspan="1">XF5 (mouse)/Xp22.2 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">ssRNA</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B74" ref-type="bibr">Tanji et al., 2013</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR9</td><td valign="top" align="left" rowspan="1" colspan="1">9F1 (mouse)/3p21.2 (human)</td><td valign="top" align="left" rowspan="1" colspan="1">Unmethylated CpG DNA, 5&#8242;-xCx DNA</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B54" ref-type="bibr">Ohto et al., 2018</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR11</td><td valign="top" align="left" rowspan="1" colspan="1">11C1 (mouse)</td><td valign="top" align="left" rowspan="1" colspan="1">Profilin of <italic toggle="yes">Toxoplasma gondii</italic></td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B46" ref-type="bibr">Lester and Li, 2014</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR12</td><td valign="top" align="left" rowspan="1" colspan="1">4D2.2 (mouse)</td><td valign="top" align="left" rowspan="1" colspan="1">Profilin of <italic toggle="yes">Toxoplasma gondii</italic></td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B46" ref-type="bibr">Lester and Li, 2014</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">TLR13</td><td valign="top" align="left" rowspan="1" colspan="1">XD (mouse)</td><td valign="top" align="left" rowspan="1" colspan="1">Bacterial 23S rRNA</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B55" ref-type="bibr">Oldenburg et al., 2012</xref>
</td></tr></tbody></table></table-wrap><p>Cell surface TLRs mainly recognize microbial membrane components such as lipoproteins, lipids, and proteins. TLR2 forms heterodimers with either TLR1 or TLR6. It recognizes a wide variety of PAMPs including lipoproteins, lipopeptides, peptidoglycans, and zymosan (<xref rid="B88" ref-type="bibr">Yu and Feng, 2018</xref>). TLR4 is mainly expressed on cells of the immune system, including macrophages, monocytes, and dendritic cells (DCs). TLR4 recognizes bacterial lipopolysaccharide (LPS) and its activation leads to the synthesis of proinflammatory cytokines and chemokines (<xref rid="B78" ref-type="bibr">Vaure and Liu, 2014</xref>). TLR5 is known to specifically sense and recognize bacterial flagellins (<xref rid="B86" ref-type="bibr">Yang and Yan, 2017</xref>). The ligands of TLR10 remain unclear but it is believed that human TLR10 collaborates with TLR2 to recognize ligands from <italic toggle="yes">Listeria</italic> and senses influenza A virus during infection; however, TLR10 has no function in mice due to an insertion of a stop codon (<xref rid="B36" ref-type="bibr">Kawasaki and Kawai, 2014</xref>).</p><p>Intracellular TLRs can recognize nucleic acids derived from foreign pathogens and self-derived nucleic acids in the context of some autoimmune diseases (<xref rid="B66" ref-type="bibr">Schlee and Hartmann, 2016</xref>). TLR3 is widely distributed in various epithelial cells, fibroblasts, nerve cells and immune cells. TLR3 mainly recognizes viral double-stranded RNA (dsRNA), self-RNAs derived from damaged cells and the replication intermediates generated during the life cycle of single-stranded RNA (ssRNA) viruses and DNA viruses (<xref rid="B77" ref-type="bibr">Turton et al., 2020</xref>). TLR7 is localized to endosomes and is mainly expressed by B cells, monocytes and plasmacytoid DCs (pDCs), while TLR8 expression is closely associated with conventional DCs (cDCs). TLR7/8 can recognize ssRNA and activate MyD88-dependent pathways, which lead to the subsequent production of type I interferons (IFNs) and inflammatory cytokines (<xref rid="B35" ref-type="bibr">Kawai and Akira, 2011</xref>; <xref rid="B33" ref-type="bibr">Jung and Lee, 2021</xref>). TLR9 recognizes unmethylated CpG-DNA motifs which are frequently presented in viral and bacterial DNA, and activates the innate immune response to eliminate these pathogens. In addition, TLR9 also binds to the DNA sequences that contain cytosine in the second position from the 5&#8242; end (5&#8242;-xCx DNA), which cooperatively promotes dimerization and activation of TLR9 in the presence of CpG DNA (<xref rid="B54" ref-type="bibr">Ohto et al., 2018</xref>). TLR11 is located to endolysosomes, and TLR12 is predominantly expressed in myeloid cells. These TLRs function in recognizing profilin from the parasites (<xref rid="B46" ref-type="bibr">Lester and Li, 2014</xref>). TLR13, the orphan receptor in mice, was found to recognize a conserved 23S ribosomal RNA (rRNA) sequence in bacteria (<xref rid="B81" ref-type="bibr">Wang et al., 2016</xref>).</p></sec><sec id="S3"><title>Toll-Like Receptor Recognition of Severe Acute Respiratory Syndrome Coronavirus 2 Components</title><sec id="S3.SS1"><title>Structure of Severe Acute Respiratory Syndrome Coronavirus 2</title><p>Viral proteins and nucleic acids can serve as PAMPs, which are sensed by TLRs to induce the production of antiviral and inflammatory cytokines. Thus, it is quite necessary to understand the nucleic acid composition and protein structure of SARS-CoV-2. Similar to other coronaviruses, SARS-CoV-2 is a positive-sense single-stranded RNA (+ssRNA) virus and its genome is approximately 29.9 kb in size; this genome mainly encodes four major structural proteins, including the spike (S), nucleocapsid (N), membrane (M), and envelope (E) proteins. The S protein consists of the receptor binding subunit S1 and the membrane fusing subunit S2. S1 includes a N-terminal domain (NTD), receptor-binding domain (RBD), subdomain 1 (SD1) and subdomain 2 (SD2). S2 includes a fusion peptide (FP), heptad repeat 1 (HR1), heptad repeat 2 (HR2), and transmembrane (TM). The rest of the genome includes two major open reading frames (ORFs)-ORF1a and ORF1b, which can be translated to pp1a and pp1b polypeptides, and then cleaved to form 16 non-structural proteins (<xref rid="B90" ref-type="bibr">Zhang et al., 2021</xref>).</p></sec><sec id="S3.SS2"><title>Toll-Like Receptors Recognize Viral Proteins and RNA of Severe Acute Respiratory Syndrome Coronavirus 2</title><p>When an infection occurs, viruses enter the body and adhere to cell surfaces. Cell surface TLRs are most likely to be involved in recognizing molecular patterns from SARS-CoV-2 to induce immune responses. The S protein is a major structural protein and is essential for the interaction of SARS-CoV-2 with host cell receptors. In addition to its direct binding to angiotensin-converting enzyme II (ACE2), the S protein is a potent viral PAMP that is sensed by TLR2 in macrophages, monocytes, and lung epithelial cells. Then TLR2 forms heterodimers with TLR1 or TLR6, promoting formation of a complex containing MyD88 with IRAK kinase family members, activating nuclear factor-&#954;B (NF-&#954;B) and mitogen-activated protein kinase (MAPK) signaling, and ultimately leading to the production of inflammatory cytokines and chemokines (<xref rid="B40" ref-type="bibr">Khan et al., 2021</xref>). SARS-CoV-2 infection also increases the expression of TLR2 and other molecules, such as melanoma differentiation-associated gene 5 (MDA5), ACE2 and interferon regulatory factor 3 (IRF3) (<xref rid="B52" ref-type="bibr">Mohanty et al., 2021</xref>; <xref rid="B84" ref-type="bibr">Yang et al., 2022</xref>), and the expression of TLR2 is positively associated with the severity of COVID-19 (<xref rid="B92" ref-type="bibr">Zheng et al., 2021</xref>). In addition to the S protein, the immunogenic properties of other structural proteins have also been investigated. Recent reports have found that TLR2 binds to the SARS-CoV-2 E and N proteins, but only the SARS-CoV-2 N protein induces TLR2 activation, which was not observed with other coronavirus-derived N proteins (<xref rid="B60" ref-type="bibr">Qian et al., 2021</xref>; <xref rid="B92" ref-type="bibr">Zheng et al., 2021</xref>). TLR4 is well known to recognize bacterial LPS. Actually, TLR4 was found to exhibit a very strong ability to bind to the S protein of SARS-CoV-2 by molecular docking studies (<xref rid="B13" ref-type="bibr">Choudhury and Mukherjee, 2020</xref>), and a surface plasmon resonance (SPR) assay confirmed that trimeric SARS-CoV-2 S protein, which is presented on the surface of viral particles, directly binds to TLR4 with a high affinity of &#8764;300 nM (<xref rid="B91" ref-type="bibr">Zhao et al., 2021</xref>). These findings suggest that TLR4 also plays a potential role in the recognition of SARS-CoV-2. This hypothesis has been supported by other evidence demonstrating that the S1 subunit of S protein elicits inflammatory responses <italic toggle="yes">in vitro</italic> and signals through TLR4. The direct exposure of microglia, macrophages, or TLR4 signaling transgenic HEK293 cells to S1 could activate the MyD88-dependent pathway, resulting in the upregulated expression of proinflammatory cytokines (<xref rid="B67" ref-type="bibr">Shirato and Kizaki, 2021</xref>; <xref rid="B21" ref-type="bibr">Frank et al., 2022</xref>). Moreover, the responses induced by S1 could be blocked by the TLR4-specific inhibitor Resatorvid or TLR4 siRNA (<xref rid="B67" ref-type="bibr">Shirato and Kizaki, 2021</xref>; <xref rid="B91" ref-type="bibr">Zhao et al., 2021</xref>). Taken together, these findings suggested that the TLR2 and TLR4 can sense SARS-CoV-2 structural proteins, and they may function independently to induce inflammatory processes (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Toll-like receptor-mediated antiviral and inflammatory responses during SARS-CoV-2 infection. TLR1/2/6 and 4 localize to cell membrane, and TLR3, TLR7/8, and 9 localize to endosome surface. The viral proteins of SARS-CoV-2 signal through TLR2 and TLR4 to activate the adaptor MyD88, which subsequently signals <italic toggle="yes">via</italic> NF-&#954;B and MAPK to promote the expression of proinflammatory cytokines. TLR4 also recruits the adapter protein TRIF, which activates the TRAF3, resulting the IRF3 activation to lead the production of type I and III IFN. The ssRNA or dsRNA replication intermediates of SARS-CoV-2 are recognized by TLR3 and TLR7/8, respectively. The TLR7/8 recruit MyD88, and TLR3 <italic toggle="yes">via</italic> TRIF molecule. The proinflammatory cytokines induced by DAMPs accumulating during SARS-CoV-2 infection are driven by the transcription factor NF-&#954;B. MAL, MyD88 adapter-like; TRAF, tumor necrosis factor receptor-associated factor; TRIF, TIR-domain-containing adapter-inducing interferon-&#946;; TRAM, TRIF-related adaptor molecule; IRAK1/4, interleukin-1 receptor associated kinase 1/4; TAK1, transforming growth factor &#946;-activated kinase 1; TAB, TAK1-binding proteins; IKK, IkB kinase; TBK1, TANK-binding kinase 1; ERK1/2, extracellular signal-regulated kinases 1/2; JNK, c-Jun N-terminal kinase; AP-1, activating protein-1.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fmicb-13-948770-g001.jpg"/></fig><p>When the SARS-CoV-2 binds to a host cell receptor such as ACE2, it fuses to the host cell membrane and releases its contents into the cell. Viral ssRNA and its replication intermediate dsRNA, are likely to be initially detected by host cells <italic toggle="yes">via</italic> TLR7/8 and TLR3 in endosomes. Previous studies showed that SARS-CoV-2 infection of Calu-3/MRC-5 multicellular spheroids induced the activation of both the TLR3 and TLR7/8 RNA sensor pathways (<xref rid="B8" ref-type="bibr">Bortolotti et al., 2021</xref>). Subsequently, TLR7/8 signaling engages the IRF-7 and MyD88-NF-&#954;B signaling pathways, leading to the increased production of type I IFNs and proinflammatory cytokines (<xref rid="B33" ref-type="bibr">Jung and Lee, 2021</xref>). In particular, TLR3 signaling relies on the TRIF adaptor protein but not the MyD88 adaptor protein. TRIF interacts with TRAF6 and TRAF3, leading to the activation of IRF3, which results in the release of IFN-&#945; and IFN-&#946; (<xref rid="B36" ref-type="bibr">Kawasaki and Kawai, 2014</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec id="S4"><title>Toll-Like Receptor-Mediated Antiviral and Inflammatory Responses Against Severe Acute Respiratory Syndrome Coronavirus 2: A Double-Edged Sword</title><p>It is well-known that TLR signaling plays a key role in host defense against many pathogens including SARS-CoV-2. However, TLR activation can act as a double-edged sword, and it may activate immune-mediated pathogenesis instead of inducing an immune response that defends against pathogens.</p><sec id="S4.SS1"><title>Toll-Like Receptor Signaling as an Antiviral Mechanism During Severe Acute Respiratory Syndrome Coronavirus 2 Infection</title><p>The IFN signaling cascade induced by TLR activation is crucial for controlling SARS-CoV-2 infection. As mentioned above, during SARS-CoV-2 infection, the expression of TLRs, such as TLR3 and TLR7, is elevated (<xref rid="B33" ref-type="bibr">Jung and Lee, 2021</xref>), and activated TLR3, TLR4 and TLR7/8 can interact with the signaling adaptor TRIF, inducing the phosphorylation and translocation of IRF3 and IRF7 and the transcription of type I and III IFN genes. Mice lacking the TLR3 gene are prone to SARS-CoV-2 infection and have increased mortality rates (<xref rid="B76" ref-type="bibr">Totura et al., 2015</xref>). Additionally, TLR copy numbers also play a role in the production of IFN; for example, the TLR7 and TLR8 genes are located on the X chromosome. Therefore, TLR7/8 copy numbers are higher in women than in men and their biallelic expression leads to the stronger activation of TLR7/8 and more production of type I IFN. These phenomena are correlated with higher resistance to SARS-CoV-2 infection and better prognosis in women (<xref rid="B80" ref-type="bibr">Viveiros et al., 2021</xref>). Moreover, loss-of-function variants of TLR7 have recently been reported to underlie a strong predisposition to severe COVID-19 in a small number of males (<xref rid="B19" ref-type="bibr">Fallerini et al., 2021</xref>). Both type I and III IFNs can induce an antiviral transcriptional program (<xref rid="B56" ref-type="bibr">Park and Iwasaki, 2020</xref>), thus, dysregulation of host IFN responses has been shown to be associated with severe disease progression in COVID-19 patients. For example, pDCs use TLR7 to sense ssRNA fragments from viruses that are rich in guanine and uracil (GU rich), and TLR7 seems to mainly act <italic toggle="yes">via</italic> the MyD88-TRAF3/6 pathway, inducing the production of type I IFN, IFN-&#947;, and IFN-&#955;3 and the upregulation of CD86 expression (<xref rid="B8" ref-type="bibr">Bortolotti et al., 2021</xref>; <xref rid="B64" ref-type="bibr">Salvi et al., 2021</xref>). However, the pDCs response of COVID-19-infected patients is functionally impaired (<xref rid="B12" ref-type="bibr">Choi and Shin, 2021</xref>).</p><p>In addition, peripheral blood immune cells from severe COVID-19 patients exhibit diminished type I and III IFN responses but enhanced proinflammatory IL-6 and TNF-&#945; responses (<xref rid="B7" ref-type="bibr">Blanco-Melo et al., 2020</xref>; <xref rid="B27" ref-type="bibr">Hadjadj et al., 2020</xref>). Analysis of the serum from critical COVID-19 patients showed the levels of proinflammatory cytokines and chemokines are strongly elevated while the levels of type I and III IFNs are undetectable (<xref rid="B56" ref-type="bibr">Park and Iwasaki, 2020</xref>). Notably, SARS-CoV-2 also possesses some strategies to escape the innate immune response due to a wide range of viral proteins, such as the M, NSP6, NSP13, NSP15, ORF3b, ORF6, ORF8, and ORF9b proteins, that affect the IFN-mediated antiviral responses (<xref rid="B32" ref-type="bibr">Jiang et al., 2020</xref>; <xref rid="B43" ref-type="bibr">Konno et al., 2020</xref>; <xref rid="B45" ref-type="bibr">Lei et al., 2020</xref>; <xref rid="B28" ref-type="bibr">Han et al., 2021</xref>; <xref rid="B70" ref-type="bibr">Sui L. et al., 2021</xref>). Therefore, future investigations are still required to obtain a clear understanding of the inhibition of TLR signaling by SARS-CoV-2.</p></sec><sec id="S4.SS2"><title>Toll-Like Receptor Signaling as a Part of the Inflammatory Response During Severe Acute Respiratory Syndrome Coronavirus 2 Infection</title><p>The activation of TLRs plays a dual role in the progression of COVID-19. It is thought that the production of proinflammatory cytokines is induced by the activation of different TLRs, such as TLR2, TLR4, and TLR7/8, which greatly contributes to the pathogenesis of COVID-19 and its severity. Immunopathological processes that cause death in COVID-19 patients occur due to the interaction of TLRs with virus particles (<xref rid="B58" ref-type="bibr">Patra et al., 2021</xref>). TLR2 and TLR4 sense viral proteins, and the expression levels of molecules related to the TLR2- and TLR4-inflammatory signaling molecules are upregulated in in COVID-19 patients, which suggest the involvement of TLR2 and TLR4 signaling in the induction of pathological inflammation during COVID-19 (<xref rid="B68" ref-type="bibr">Sohn et al., 2020</xref>). Moreover, several studies have shown that an overwhelming TLR7 response may promote the development of severe COVID-19 (<xref rid="B19" ref-type="bibr">Fallerini et al., 2021</xref>; <xref rid="B37" ref-type="bibr">Kayesh et al., 2021</xref>), highlighting the clinical importance of the TLR-mediated immune response during SARS-CoV-2 infection. Moreover, other studies on SARS-CoV-2 have revealed the pathological role of TLR4 and TLR7/8 in excessive inflammatory response in COVID-19 patients as it leads to the formation of neutrophil extracellular traps (NETs) and the activation of inflammasomes, leading to acute lung injury (<xref rid="B38" ref-type="bibr">Khadke et al., 2020</xref>; <xref rid="B68" ref-type="bibr">Sohn et al., 2020</xref>; <xref rid="B79" ref-type="bibr">Veras et al., 2020</xref>).</p><p>Additionally, obese and overweight individuals exhibit significantly increased TLR expression, which impacts the severity of COVID-19. It is hypothesized that desensitization of TLR signaling may occur due to chronic stimulation in obese and elderly people. TLR/MyD88 signaling, which is enhanced in obese individuals, may contribute to the excessive inflammatory response observed during severe infection with SARS-CoV-2 (<xref rid="B16" ref-type="bibr">Cuevas et al., 2021</xref>). Similarly, significantly elevated expression of IL-6 and TNF-&#945; was observed to be associated with TLR expression in obese individuals but not in controls (<xref rid="B37" ref-type="bibr">Kayesh et al., 2021</xref>). Moreover, delayed IFN responses fail to control the virus and can cause inflammation and tissue damage. Delayed but considerable type I IFN responses in SARS-CoV-2 infected BALB/c mice trigger the accumulation of monocytes and macrophages as well as the production of proinflammatory cytokines, resulting in lethal pneumonia, vascular leakage, and insufficient T-cell responses (<xref rid="B10" ref-type="bibr">Channappanavar et al., 2016</xref>).</p><p>Furthermore, damage to host cell caused by SARS-CoV-2 infection can also lead to the release of endogenous danger-associated molecular patterns (DAMPs). These endogenous self-antigens, such as high-mobility group box 1 (HMGB1) and heat shock proteins (HSPs), activate MAPK and NF-&#954;B signaling, which triggers an inflammatory response. In COVID-19 patients, HMGB1 can be released from dying cells and functions as a pro-inflammatory inducer to bind with TLR4, leading to the production of IL-1&#946;, IL-6, and TNF-&#945; (<xref rid="B85" ref-type="bibr">Yang et al., 2015</xref>; <xref rid="B14" ref-type="bibr">Cicco et al., 2020</xref>). Another DAMP shown to regulate inflammation during SARS-CoV-2 infection is the S100A8/A9 complex, which is released from host neutrophils and has been proposed to be a potential biomarker in COVID-19 patients. Mechanistically, the S100A8/A9 complex is also an endogenous ligand of TLR4 on DCs and mediates host proinflammatory responses (<xref rid="B51" ref-type="bibr">Mellett and Khader, 2022</xref>). TLR9 is not directly involved in recognition of SARS-CoV-2. However, cell-free DNA (cfDNA) production that is triggered by tissue injury during virus infection, cfDNA can subsequently act as a DAMP and exacerbates inflammation <italic toggle="yes">via</italic> TLR9. Recent studies have reported that elevated levels of cfDNA in COVID-19 patients are strongly correlated with COVID-19 disease severity (<xref rid="B2" ref-type="bibr">Andargie et al., 2021</xref>; <xref rid="B9" ref-type="bibr">Cavalier et al., 2021</xref>). Moreover, the increased cfDNA levels in COVID-19 patients generates excessive mitochondrial ROS (mtROS) production in a concentration-dependent manner (<xref rid="B2" ref-type="bibr">Andargie et al., 2021</xref>). Taken together, these findings suggest that host molecules that are released during SARS-CoV-2 infection may function independently as DAMPs, resulting in a more severe inflammatory response (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p></sec></sec><sec id="S5"><title>Toll-Like Receptor Agonists as Adjuvants for Coronavirus Disease 2019 Vaccines</title><p>More efficient and safe vaccines are still a critical need for combating COVID-19. In vaccine development, adjuvants are required to increase antigen recognition and enhance the magnitude and durability of the elicited immune responses. TLR agonists are considered important molecules for triggering and enhancing rapid and long-term innate immune responses, and they have been extensively studied for use as vaccine adjuvants against cancer and microbial infections. Compared to the first-generation adjuvants, such as aluminum adjuvant, TLR agonist adjuvants could guide DC maturation to elicit a stronger T-cell response. Various TLR agonists, including Pam3CSK4, poly(I:C), monophosphoryl lipid A (MPLA), resiquimod (R848), and CpG oligonucleotide (ODN), are currently under investigation for use as vaccine adjuvants to prevent SARS-CoV-2 infection. The TLR agonists currently under development for COVID-19 vaccines are listed in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>TABLE 2</label><caption><p>Toll-like receptor agonists as vaccine adjuvants in COVID-19 vaccine formulation.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR agonists</td><td valign="top" align="left" rowspan="1" colspan="1">Platform</td><td valign="top" align="left" rowspan="1" colspan="1">Adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">Antigen</td><td valign="top" align="left" rowspan="1" colspan="1">Formulation</td><td valign="top" align="center" colspan="3" rowspan="1">Immunological response<hr/></td><td valign="top" align="left" rowspan="1" colspan="1">Route</td><td valign="top" align="left" rowspan="1" colspan="1">Animal model or clinical trial</td><td valign="top" align="left" rowspan="1" colspan="1">References</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Nab</td><td valign="top" align="left" rowspan="1" colspan="1">sIgA</td><td valign="top" align="left" rowspan="1" colspan="1">T-cell response</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR 1/2</td><td valign="top" align="left" rowspan="1" colspan="1">Peptide vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">XS15</td><td valign="top" align="left" rowspan="1" colspan="1">T-cell epitopes from viral protein</td><td valign="top" align="left" rowspan="1" colspan="1">Montanide ISA 51 VG</td><td valign="top" align="left" rowspan="1" colspan="1">Weak</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T and IFN-&#947; response</td><td valign="top" align="left" rowspan="1" colspan="1">SC</td><td valign="top" align="left" rowspan="1" colspan="1">Phase II trial</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B61" ref-type="bibr">Rammensee et al., 2021</xref>; <xref rid="B30" ref-type="bibr">Heitmann et al., 2022</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR 1/2 and TLR3</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">L-pampo</td><td valign="top" align="left" rowspan="1" colspan="1">RBD and S1 antigens</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#947; response</td><td valign="top" align="left" rowspan="1" colspan="1">IM</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c and ferret</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B31" ref-type="bibr">Jeong et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR3</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus-based vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">dsRNA</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 S and N gene</td><td valign="top" align="left" rowspan="1" colspan="1">Adenovirus</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">Moderate</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Oral</td><td valign="top" align="left" rowspan="1" colspan="1">Hamsters and phase I trial</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B75" ref-type="bibr">Tiboni et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR3</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">PIKA</td><td valign="top" align="left" rowspan="1" colspan="1">Trimeric S antigen</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Balanced Th1/Th2 and IFN-&#947; response</td><td valign="top" align="left" rowspan="1" colspan="1">IM</td><td valign="top" align="left" rowspan="1" colspan="1">Rabbits, mice, and non-human primates</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B49" ref-type="bibr">Liu Y. et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR3 and TLR9</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">CpG ODN + poly I:C + IL-15</td><td valign="top" align="left" rowspan="1" colspan="1">S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">PLGA or DOTAP</td><td valign="top" align="left" rowspan="1" colspan="1">Weak</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T response</td><td valign="top" align="left" rowspan="1" colspan="1">IM, IN</td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus macaques</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B71" ref-type="bibr">Sui Y. et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR4</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">MPLA + PUUC</td><td valign="top" align="left" rowspan="1" colspan="1">S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">Polymer nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">Memory T-cell response</td><td valign="top" align="left" rowspan="1" colspan="1">IN, IM</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B4" ref-type="bibr">Atalis et al., 2022</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR-4</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">MPLA + GM-CSF</td><td valign="top" align="left" rowspan="1" colspan="1">SARS-CoV-2 N/S1/S2 proteins</td><td valign="top" align="left" rowspan="1" colspan="1">MSRs</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> and CD8<sup>+</sup> T response</td><td valign="top" align="left" rowspan="1" colspan="1">SC</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B44" ref-type="bibr">Langellotto et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7/8</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Alhydroxiquim-II</td><td valign="top" align="left" rowspan="1" colspan="1">Trimeric spike antigen</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T</td><td valign="top" align="left" rowspan="1" colspan="1">IM</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6, rabbits, horses</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B15" ref-type="bibr">Counoupas et al., 2022</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7/8</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">R848</td><td valign="top" align="left" rowspan="1" colspan="1">S1 protein</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoparticle decorated erythrocytes</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T response</td><td valign="top" align="left" rowspan="1" colspan="1">IV</td><td valign="top" align="left" rowspan="1" colspan="1">C57BL/6</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B83" ref-type="bibr">Wang et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR7/8</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Chemisorbed Algel</td><td valign="top" align="left" rowspan="1" colspan="1">Inactivated antigen</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T and Th1-biased responses</td><td valign="top" align="left" rowspan="1" colspan="1">IM</td><td valign="top" align="left" rowspan="1" colspan="1">Mice, rats, and rabbits</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B24" ref-type="bibr">Ganneru et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR-7 or TLR-9</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">AS37-Alum or CpG 1018-Alum</td><td valign="top" align="left" rowspan="1" colspan="1">RBD antigen</td><td valign="top" align="left" rowspan="1" colspan="1">Self-assembling protein nanoparticle</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T response</td><td valign="top" align="left" rowspan="1" colspan="1">IM</td><td valign="top" align="left" rowspan="1" colspan="1">Rhesus macaques and phase II trial</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="B3" ref-type="bibr">Arunachalam et al., 2021</xref>; <xref rid="B62" ref-type="bibr">Richmond et al., 2021</xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR9</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">CpG SD-101</td><td valign="top" align="left" rowspan="1" colspan="1">RBD mRNA</td><td valign="top" align="left" rowspan="1" colspan="1">CART</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> and CD8<sup>+</sup> T</td><td valign="top" align="left" rowspan="1" colspan="1">IV, IM</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B26" ref-type="bibr">Haabeth et al., 2021</xref>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TLR-9</td><td valign="top" align="left" rowspan="1" colspan="1">Subunit vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">CpG 7909-Alum</td><td valign="top" align="left" rowspan="1" colspan="1">Trimeric S antigen</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">Strong</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td><td valign="top" align="left" rowspan="1" colspan="1">CD4<sup>+</sup> T response</td><td valign="top" align="left" rowspan="1" colspan="1">IM</td><td valign="top" align="left" rowspan="1" colspan="1">BALB/c and monkeys</td><td valign="top" align="left" rowspan="1" colspan="1">
<xref rid="B48" ref-type="bibr">Liu H. et al., 2021</xref>
</td></tr></tbody></table><table-wrap-foot><fn><p>
<italic toggle="yes">NA, not available; Nab, naturalization antibody; SC, subcutaneous; IM, intramuscular; IV, intravenous; IN, intranasal; PUUC, RIG-I agonist; PLGA, poly(lactic-co-glycolic acid); DOTAP, 1,2-dioleoyl-3-trimethylammonium-propane; CART, charge-altering releasable transporters.</italic>
</p></fn></table-wrap-foot></table-wrap><sec id="S5.SS1"><title>Toll-Like Receptor 1/2 Agonists</title><p>The TLR1/TLR2 ligand Pam3CSK4 is a synthetic triacylated lipopeptide and can activate the proinflammatory transcription factor NF-&#954;B. A new water-soluble synthetic Pam3CSK4-derivative, named XS15, is being used in combination with peptides from the SARS-CoV-2 spike protein to develop a vaccine format that induces CD4<sup>+</sup> T-cell responses against peptides predicted to bind to HLA-DR (<xref rid="B61" ref-type="bibr">Rammensee et al., 2021</xref>). In a phase I open-label trial, a peptide-based vaccine CoVac-1, which is composed of T-cell epitopes derived from various SARS-CoV-2 proteins, was combined with XS15 and emulsified in Montanide ISA 51 VG. This vaccine induced profound SARS-CoV-2-specific T-cell responses targeting multiple vaccine peptides in all the study participants. Moreover, the interferon (IFN)-&#947; T-cell responses induced by CoVac-1 persisted in the follow-up analyses and surpassed those detected after vaccination with approved vaccines (<xref rid="B30" ref-type="bibr">Heitmann et al., 2022</xref>). In addition, in a study of a SARS-CoV-2 subunit vaccine, a combination of TLR1/2 and TLR3 agonists (L-pampo) was found to be a potent adjuvant for eliciting a neutralization antibody response and an antigen-specific cellular immune response against SARS-CoV-2, resulting in a substantially decreased viral load in a ferret model (<xref rid="B31" ref-type="bibr">Jeong et al., 2021</xref>).</p></sec><sec id="S5.SS2"><title>Toll-Like Receptor 4 Agonists</title><p>The TLR4 ligand LPS can regulate inflammation and effector T-cell differentiation. MPLA is a modified form of LPS that exhibits strong immune stimulatory activity but avoids most inflammatory toxicity. It has been approved for utilization as an adjuvant in vaccines against human papilloma virus and hepatitis B virus. In a previous vaccine study, MPLA-adjuvanted truncated spike protein fused with Fc of human IgG (S377-588-Fc) induced a significantly higher titer of specific IgG antibodies against Middle East respiratory syndrome coronavirus than did the alum-adjuvanted protein. In particular, MPLA-adjuvanted S377-588-Fc protein elicited a stronger Th2 (IgG1)-biased response (<xref rid="B89" ref-type="bibr">Zhang et al., 2016</xref>). Recently, a biomaterial COVID-19 vaccine based on mesoporous silica rods (MSRs) and loaded with MPLA, granulocyte-macrophage colony-stimulating factor (GM-CSF), and SARS-CoV-2 viral protein antigens was shown to slowly release their cargo and form subcutaneous scaffolds that recruited and activated antigen-presenting cells (APCs) at the local site to generate adaptive immune responses (<xref rid="B44" ref-type="bibr">Langellotto et al., 2021</xref>). The SARS-CoV-2 is still mutating; however, the MPLA-adjuvanted antigens like S-trimer/MPLA, RBD/MPLA, and S1/MPLA remain to induce a strong humoral and cellular immune responses against spike variants, including alpha, beta, gamma, delta, and omicron (<xref rid="B82" ref-type="bibr">Wang et al., 2022</xref>). Another TLR4 agonist, inulin acetate (InAc), which is a plant-based polymer, has been reported to induce high IgG1, IgG2a, and sIgA titers against antigens in serum after intranasal immunization using antigen-loaded InAc nanoparticles (InAc-NPs); this approach resulted in a strong memory response indicative of both humoral and cellular immune activation, and may be useful in the development of a COVID-19 vaccine (<xref rid="B5" ref-type="bibr">Bakkari et al., 2021</xref>).</p></sec><sec id="S5.SS3"><title>Toll-Like Receptor 7/8 Agonists</title><p>Toll-Like Receptor 7/8 activation may be investigated as an additional strategy for anti-SARS-CoV-2 vaccines address the current challenge of viral escape. TLR7 stimulation may help viral clearance through Th1 antiviral responses as well as exert beneficial broncho-vasodilatory activity (<xref rid="B39" ref-type="bibr">Khalifa and Ghoneim, 2021</xref>). As a synthetic and selective ligand for TLR7, imiquimod has been approved for human-papillomavirus-induced genital and perianal warts. An imiquimod analog, resiquimod (R848), was proven to be a dual TLR7 and TLR8 synthetic agonist that elicits prominent IFN-&#945;/&#946; and IL-6 responses and robust cytotoxic T-cell (CTL) and B-cell proliferation; thus, it is particularly suited for antiviral immune responses. Indeed, the cytokine profiles induced by R848, are almost identical to the profiles induced by the licensed mRNA vaccines against COVID-19 (<xref rid="B63" ref-type="bibr">Rossmann et al., 2021</xref>). In a SARS-CoV-2 virus-mimetic nanoparticle vaccine, the SARS-CoV-2 spike protein S1 subunit and R848 were attached to erythrocytes and injected into mice, resulting in greater maturation and activation of APCs, production of specific IgG antibodies, and systemic antiviral T-cell responses than the nanoparticles alone (<xref rid="B83" ref-type="bibr">Wang et al., 2021</xref>). However, R848 adjuvanticity should stress more on vaccine formulation. A recent study showed that R848 conjugated to multilamellar liposomes rather than forming a linear structure, resulting in stronger immunostimulatory activity (<xref rid="B47" ref-type="bibr">Liang et al., 2020</xref>). Moreover, an R848-encapsulating poly lactic-co-glycolic acid (PLGA) nanoparticle can reduce the excessive level of inflammatory cytokines induced by free R848 (<xref rid="B11" ref-type="bibr">Chen et al., 2021</xref>), which could be beneficial for providing an appropriate immune response and long-term safety in vaccine development.</p></sec><sec id="S5.SS4"><title>Toll-Like Receptor 3/9 Agonists</title><p>Optimal protection against coronavirus probably involves neutralizing antibodies and CD8<sup>+</sup> T cells. Among the TLR agonists, the TLR3 and TLR9 ligands, poly(I:C) and CpG ODN significantly augment the CD8<sup>+</sup> T-cell responses to a greater extent than other adjuvants. Thus, CpG ODN and poly(I:C) have been utilized as adjuvants in influenza vaccines. Studies have demonstrated that CpG ODN or PIKA [a stabilized derivative of poly(I:C)] can stimulate enhanced IgG production in animals have been used in the context of immunization with an inactivated SARS-CoV-2 vaccine (<xref rid="B23" ref-type="bibr">Gai et al., 2008</xref>; <xref rid="B25" ref-type="bibr">Gupta and Gupta, 2020</xref>). Moreover, compared with the alum adjuvanted SARS-CoV-2 S1 vaccine, intranasal boosting with nanoparticles, formulating with CpG 1018 and poly(I:C), elicits higher dimeric IgA production, IFN-&#945; production, and T-cell activation in rhesus macaques (<xref rid="B71" ref-type="bibr">Sui Y. et al., 2021</xref>). In another study, a recombinant S trimeric protein adjuvanted with PIKA was reported to induce high titers of SARS-CoV-2 neutralizing antibodies and to protect non-human primates from virus challenge (<xref rid="B49" ref-type="bibr">Liu Y. et al., 2021</xref>). Another CpG ODN 7909-adjuvanted SARS-CoV-2 vaccine, 202-COV, is a S-protein subunit vaccine formulated with aluminum hydroxide; that elicits robust neutralizing antibody responses and substantial CD4<sup>+</sup> T-cell responses in both mice and non-human primates; this vaccine is currently being investigated in phase II studies of COVID-19 (<xref rid="B48" ref-type="bibr">Liu H. et al., 2021</xref>). CpG ODN is capable of inducing both cellular and humoral immune responses, and it preferentially induces Th1-biased responses. Mice that were immunized with mRNA encoding the spike protein of SARS-CoV-2, co-formulated with CpG ODN, developed therapeutically relevant levels of RBD-specific neutralizing antibodies in both circulation and lung bronchial fluids. In addition, vaccination elicited strong and long-lasting RBD-specific Th1 T-cell responses including CD4<sup>+</sup> and CD8<sup>+</sup> T-cell memory responses (<xref rid="B26" ref-type="bibr">Haabeth et al., 2021</xref>).</p></sec></sec><sec id="S6"><title>Toll-Like Receptor Signaling Inhibitors Protect Against Hyperinflammatory Response in Severe Acute Respiratory Syndrome Coronavirus 2 Infection</title><p>Uncontrolled TLR-mediated inflammation has been suggested to contribute to immunopathological consequences in COVID-19 patients. It is quite obvious that targeted manipulation of TLR signaling decreases excessive inflammatory responses. TLR4 is one of the major contributors to SARS-CoV-2 infectivity and pathogenesis, and its antagonists are capable of inhibiting the harmful effects of TLR4 signaling. For example, Lipid X is a Lipid A biosynthetic precursor that can competitively bind to TLR4 to block cytokine production <italic toggle="yes">via</italic> the downstream signaling pathways. Therefore, many TLR4 modulators, both natural and synthetic, can be investigated in the context of COVID-19 treatment. TAK242 is a potent and selective TLR4 antagonist that inhibits the release of inflammatory cytokines from human THP-1 cells after exposure to SARS-CoV-2. Therefore, it is postulated that TAK242 may improve patient outcomes by dampening the inflammatory response and preventing systemic infection in patients with COVID-19 (<xref rid="B34" ref-type="bibr">Kate Gadanec et al., 2021</xref>).</p><p>The intracellular RNA sensors TLR3 and TLR7/8 are thought to be involved in the hyperinflammatory responses induced by SARS-CoV-2 infection. A TLR7/8 antagonist, Enpatoran (M5049), is a potent dual TLR7/8 inhibitor that is expected to cease the hyperinflammatory milieu in symptomatic patients with COVID-19. Furthermore, Merck has already initiated a phase II randomized, controlled clinical study evaluating the efficacy and safety of M5049 in the COVID-19 patient population (<xref rid="B39" ref-type="bibr">Khalifa and Ghoneim, 2021</xref>; <xref rid="B59" ref-type="bibr">Port et al., 2021</xref>). Similarly, famotidine, a specific histamine H2 receptor antagonist, can inhibit TLR3 expression in SARS-CoV-2 infected cells and reduce TLR3-dependent NF-&#954;B and IRF3 signaling, subsequently controlling antiviral and inflammatory responses (<xref rid="B53" ref-type="bibr">Mukherjee et al., 2021</xref>) and reducing the risk of intubation and death in hospitalized patients with COVID-19 (<xref rid="B22" ref-type="bibr">Freedberg et al., 2020</xref>). Another TLR signaling inhibitor, the PPAR&#945; agonist oleoylethanolamide (OEA), was reported to attenuate TLR3-induced hyperthermia and reduce the expression of hyperthermia-related genes including IL-1&#946;, iNOS, COX2, and m-PGES in the hypothalamus (<xref rid="B20" ref-type="bibr">Flannery et al., 2021</xref>).</p><p>Toll-like receptor antagonists are not only used as individual drugs but may also be used in combination with immunomodulatory drugs in severe cases of COVID-19 to enhance potential synergistic effects and possibly reduce adverse effects. Currently, most TLR antagonists are being investigated in clinical trials to evaluate their efficacy in reducing detrimental immune effects without causing a drastic change in their basal levels to maintain the immune homeostasis.</p></sec><sec sec-type="conclusion" id="S7"><title>Conclusion</title><p>Toll-like receptors are important constituents of the innate immune system and can recognize a wide variety of PAMPs from viruses. This review has described the various TLRs that are involved in the immunopathogenesis of SARS-CoV-2 infection and the effects of application of TLR immunomodulators in patients with COVID-19. Of the TLRs that have been identified, TLR7/TLR8 and TLR3 are intracellular receptor that sense viral ssRNA, and dsRNA replication intermediates, respectively. TLR2 and TLR4 reside on the cell surface and are activated by SARS-CoV-2 glycoproteins. TLR signaling elicits antiviral and proinflammatory cytokine production through MyD88-dependent and/or TRIF-dependent pathways. The activation of the innate immune response often contributes to viral clearance and disease resolution. Therefore, TLR agonists could be formulated as adjuvants for use with the S protein or RBD to enhance neutralizing antibody production and T-cell responses against SARS-CoV-2 infection since they elicit timely and optimal TLR responses. However, dysregulated immune signaling may lead to the detrimental production of proinflammatory cytokines and chemokines that cause severe disease. Thus, the use of TLR antagonists might exert a beneficial effect, by attenuating deleterious hyperinflammatory responses in severe COVID-19 patients. However, most of these new therapeutics or combination strategies for anti-SARS-CoV-2 infection are currently being studied in clinical trials of various phases.</p></sec><sec id="S8"><title>Author Contributions</title><p>JD, YBW, and HRW contributed to the writing of the manuscript. MY and YS provided the ideas and revised the draft manuscript. ZG, YW, MF, SS, PZ, and HW approved the version to be published. MF provided a professional English language revision. All authors read and approved the final manuscript.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="pudiscl1"><title>Publisher&#8217;s Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><sec sec-type="funding-information" id="S9"><title>Funding</title><p>This work was supported by the National Natural Science Foundation of China (grant number 81902111) and the Department of Finance of Jilin Province (grant number JLSWSRCZX2020-00107).</p></sec><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aboudounya</surname><given-names>M. M.</given-names></name><name name-style="western"><surname>Heads</surname><given-names>R. J.</given-names></name></person-group> (<year>2021</year>). <article-title>COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation.</article-title><source><italic toggle="yes">Mediators Inflamm.</italic></source><volume>2021</volume>:<fpage>8874339</fpage>. <pub-id pub-id-type="doi">10.1155/2021/8874339</pub-id><pub-id pub-id-type="pmid">33505220</pub-id><pub-id pub-id-type="pmcid">PMC7811571</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andargie</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>N.</given-names></name><name name-style="western"><surname>Seifuddin</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>M. K.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury.</article-title><source><italic toggle="yes">JCI Insight</italic></source><volume>6</volume>:<fpage>e147610</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.147610</pub-id><pub-id pub-id-type="pmid">33651717</pub-id><pub-id pub-id-type="pmcid">PMC8119224</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A. C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.</article-title><source><italic toggle="yes">Nature</italic></source><volume>594</volume><fpage>253</fpage>&#8211;<lpage>258</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-03530-2</pub-id><pub-id pub-id-type="pmid">33873199</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atalis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Keenum</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Pandey</surname><given-names>B.</given-names></name><name name-style="western"><surname>Beach</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pradhan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Vantucci</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>Nanoparticle-delivered TLR4 and RIG-I agonists enhance immune response to SARS-CoV-2 subunit vaccine.</article-title><source><italic toggle="yes">bioRxiv</italic></source>[<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2022.01.31.478507</pub-id><pub-id pub-id-type="pmid">35577151</pub-id><pub-id pub-id-type="pmcid">PMC9121740</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakkari</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Valiveti</surname><given-names>C. K.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>R. S.</given-names></name><name name-style="western"><surname>Tummala</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Toll-like Receptor-4 (TLR4) Agonist-Based Intranasal Nanovaccine Delivery System for Inducing Systemic and Mucosal Immunity.</article-title><source><italic toggle="yes">Mol. Pharm.</italic></source><volume>18</volume><fpage>2233</fpage>&#8211;<lpage>2241</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.0c01256</pub-id><pub-id pub-id-type="pmid">34010002</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birra</surname><given-names>D.</given-names></name><name name-style="western"><surname>Benucci</surname><given-names>M.</given-names></name><name name-style="western"><surname>Landolfi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Merchionda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Loi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Amato</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID 19: a clue from innate immunity.</article-title><source><italic toggle="yes">Immunol. Res.</italic></source><volume>68</volume><fpage>161</fpage>&#8211;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1007/s12026-020-09137-5</pub-id><pub-id pub-id-type="pmid">32524333</pub-id><pub-id pub-id-type="pmcid">PMC7286633</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanco-Melo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nilsson-Payant</surname><given-names>B. E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W. C.</given-names></name><name name-style="western"><surname>Uhl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoagland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moller</surname><given-names>R.</given-names></name></person-group> (<year>2020</year>). <article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.</article-title><source><italic toggle="yes">Cell</italic></source><volume>181</volume><fpage>1036</fpage>&#8211;<lpage>1045.e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id><pub-id pub-id-type="pmid">32416070</pub-id><pub-id pub-id-type="pmcid">PMC7227586</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bortolotti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gentili</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rizzo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schiuma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Beltrami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Strazzabosco</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>TLR3 and TLR7 RNA Sensor Activation during SARS-CoV-2 Infection.</article-title><source><italic toggle="yes">Microorganisms</italic></source><volume>9</volume>:<fpage>1820</fpage>. <pub-id pub-id-type="doi">10.3390/microorganisms9091820</pub-id><pub-id pub-id-type="pmid">34576716</pub-id><pub-id pub-id-type="pmcid">PMC8465566</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavalier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Guiot</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lechner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dutsch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eccleston</surname><given-names>M.</given-names></name><name name-style="western"><surname>Herzog</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression.</article-title><source><italic toggle="yes">Front. Mol. Biosci.</italic></source><volume>8</volume>:<fpage>600881</fpage>. <pub-id pub-id-type="doi">10.3389/fmolb.2021.600881</pub-id><pub-id pub-id-type="pmid">33816549</pub-id><pub-id pub-id-type="pmcid">PMC8012533</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fehr</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Vijay</surname><given-names>R.</given-names></name><name name-style="western"><surname>Mack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meyerholz</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice.</article-title><source><italic toggle="yes">Cell Host Microbe</italic></source><volume>19</volume><fpage>181</fpage>&#8211;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2016.01.007</pub-id><pub-id pub-id-type="pmid">26867177</pub-id><pub-id pub-id-type="pmcid">PMC4752723</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Nanotherapies for sepsis by regulating inflammatory signals and reactive oxygen and nitrogen species: new insight for treating COVID-19.</article-title><source><italic toggle="yes">Redox Biol.</italic></source><volume>45</volume>:<fpage>102046</fpage>. <pub-id pub-id-type="doi">10.1016/j.redox.2021.102046</pub-id><pub-id pub-id-type="pmid">34174559</pub-id><pub-id pub-id-type="pmcid">PMC8205260</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E. C.</given-names></name></person-group> (<year>2021</year>). <article-title>Roles of Type I and III Interferons in COVID-19.</article-title><source><italic toggle="yes">Yonsei Med. J.</italic></source><volume>62</volume><fpage>381</fpage>&#8211;<lpage>390</lpage>. <pub-id pub-id-type="doi">10.3349/ymj.2021.62.5.381</pub-id><pub-id pub-id-type="pmid">33908208</pub-id><pub-id pub-id-type="pmcid">PMC8084697</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choudhury</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group> (<year>2020</year>). <article-title>In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.</article-title><source><italic toggle="yes">J. Med. Virol.</italic></source><volume>92</volume><fpage>2105</fpage>&#8211;<lpage>2113</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.25987</pub-id><pub-id pub-id-type="pmid">32383269</pub-id><pub-id pub-id-type="pmcid">PMC7267663</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicco</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cicco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Racanelli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Vacca</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): two Potential Targets for COVID-19 Treatment.</article-title><source><italic toggle="yes">Mediators Inflamm.</italic></source><volume>2020</volume>:<fpage>7527953</fpage>. <pub-id pub-id-type="doi">10.1155/2020/7527953</pub-id><pub-id pub-id-type="pmid">32724296</pub-id><pub-id pub-id-type="pmcid">PMC7366221</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Counoupas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pino</surname><given-names>P.</given-names></name><name name-style="western"><surname>Stella</surname><given-names>A. O.</given-names></name><name name-style="western"><surname>Ashley</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lukeman</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bhattacharyya</surname><given-names>N. D.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens.</article-title><source><italic toggle="yes">Microbiol. Spectr.</italic></source><volume>10</volume>:<fpage>e0169521</fpage>. <pub-id pub-id-type="doi">10.1128/spectrum.01695-21</pub-id><pub-id pub-id-type="pmid">35171046</pub-id><pub-id pub-id-type="pmcid">PMC8849074</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cuevas</surname><given-names>A. M.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>J. J.</given-names></name></person-group> (<year>2021</year>). <article-title>Increased TLR/MyD88 signaling in patients with obesity: is there a link to COVID-19 disease severity?</article-title><source><italic toggle="yes">Int. J. Obes.</italic></source><volume>45</volume><fpage>1152</fpage>&#8211;<lpage>1154</lpage>. <pub-id pub-id-type="doi">10.1038/s41366-021-00768-8</pub-id><pub-id pub-id-type="pmid">33637950</pub-id><pub-id pub-id-type="pmcid">PMC7909368</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debnath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Berk</surname><given-names>M.</given-names></name></person-group> (<year>2020</year>). <article-title>Genetic gateways to COVID-19 infection: implications for risk, severity, and outcomes.</article-title><source><italic toggle="yes">FASEB J.</italic></source><volume>34</volume><fpage>8787</fpage>&#8211;<lpage>8795</lpage>. <pub-id pub-id-type="doi">10.1096/fj.202001115R</pub-id><pub-id pub-id-type="pmid">32525600</pub-id><pub-id pub-id-type="pmcid">PMC7300732</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ebermeyer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cognasse</surname><given-names>F.</given-names></name><name name-style="western"><surname>Berthelot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mismetti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Garraud</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hamzeh-Cognasse</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>Platelet Innate Immune Receptors and TLRs: a Double-Edged Sword.</article-title><source><italic toggle="yes">Int. J. Mol. Sci.</italic></source><volume>22</volume>:<fpage>7894</fpage>. <pub-id pub-id-type="doi">10.3390/ijms22157894</pub-id><pub-id pub-id-type="pmid">34360659</pub-id><pub-id pub-id-type="pmcid">PMC8347377</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallerini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Daga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Benetti</surname><given-names>E.</given-names></name><name name-style="western"><surname>Picchiotti</surname><given-names>N.</given-names></name><name name-style="western"><surname>Francisci</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study.</article-title><source><italic toggle="yes">eLife</italic></source><volume>10</volume>:<fpage>e67569</fpage>. <pub-id pub-id-type="doi">10.7554/eLife.67569</pub-id><pub-id pub-id-type="pmid">33650967</pub-id><pub-id pub-id-type="pmcid">PMC7987337</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flannery</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>D. M.</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>E. M.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>C.</given-names></name><name name-style="western"><surname>Costello</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>A. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>N-acylethanolamine regulation of TLR3-induced hyperthermia and neuroinflammatory gene expression: a role for PPARalpha.</article-title><source><italic toggle="yes">J. Neuroimmunol.</italic></source><volume>358</volume>:<fpage>577654</fpage>. <pub-id pub-id-type="doi">10.1016/j.jneuroim.2021.577654</pub-id><pub-id pub-id-type="pmid">34265624</pub-id><pub-id pub-id-type="pmcid">PMC8243641</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>K. H.</given-names></name><name name-style="western"><surname>Ball</surname><given-names>J. B.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baratta</surname><given-names>M. V.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: evidence of PAMP-like properties.</article-title><source><italic toggle="yes">Brain Behav. Immun.</italic></source><volume>100</volume><fpage>267</fpage>&#8211;<lpage>277</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbi.2021.12.007</pub-id><pub-id pub-id-type="pmid">34915155</pub-id><pub-id pub-id-type="pmcid">PMC8667429</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freedberg</surname><given-names>D. E.</given-names></name><name name-style="western"><surname>Conigliaro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T. C.</given-names></name><name name-style="western"><surname>Tracey</surname><given-names>K. J.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>M. V.</given-names></name><name name-style="western"><surname>Abrams</surname><given-names>J. A.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Famotidine Use Is Associated With Improved Clinical Outcomes in Hospitalized COVID-19 Patients: a Propensity Score Matched Retrospective Cohort Study.</article-title><source><italic toggle="yes">Gastroenterology</italic></source><volume>159</volume><fpage>1129</fpage>&#8211;<lpage>1131.e3</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.053</pub-id><pub-id pub-id-type="pmid">32446698</pub-id><pub-id pub-id-type="pmcid">PMC7242191</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.</article-title><source><italic toggle="yes">Viral Immunol.</italic></source><volume>21</volume><fpage>27</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2007.0079</pub-id><pub-id pub-id-type="pmid">18355120</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Daram</surname><given-names>V. K.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Molugu</surname><given-names>N. R.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S. D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.</article-title><source><italic toggle="yes">iScience</italic></source><volume>24</volume>:<fpage>102298</fpage>. <pub-id pub-id-type="doi">10.1016/j.isci.2021.102298</pub-id><pub-id pub-id-type="pmid">33723528</pub-id><pub-id pub-id-type="pmcid">PMC7944858</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S. K.</given-names></name></person-group> (<year>2020</year>). <article-title>Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.</article-title><source><italic toggle="yes">Int. Immunopharmacol.</italic></source><volume>86</volume>:<fpage>106717</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.106717</pub-id><pub-id pub-id-type="pmid">32585611</pub-id><pub-id pub-id-type="pmcid">PMC7301105</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haabeth</surname><given-names>O. A. W.</given-names></name><name name-style="western"><surname>Lohmeyer</surname><given-names>J. J. K.</given-names></name><name name-style="western"><surname>Sallets</surname><given-names>A.</given-names></name><name name-style="western"><surname>Blake</surname><given-names>T. R.</given-names></name><name name-style="western"><surname>Sagiv-Barfi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Czerwinski</surname><given-names>D. K.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>An mRNA SARS-CoV-2 Vaccine Employing Charge-Altering Releasable Transporters with a TLR-9 Agonist Induces Neutralizing Antibodies and T Cell Memory.</article-title><source><italic toggle="yes">ACS Cent. Sci.</italic></source><volume>7</volume><fpage>1191</fpage>&#8211;<lpage>1204</lpage>. <pub-id pub-id-type="doi">10.1021/acscentsci.1c00361</pub-id><pub-id pub-id-type="pmid">34341771</pub-id><pub-id pub-id-type="pmcid">PMC8265720</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hadjadj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yatim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barnabei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corneau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boussier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.</article-title><source><italic toggle="yes">Science</italic></source><volume>369</volume><fpage>718</fpage>&#8211;<lpage>724</lpage>. <pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmid">32661059</pub-id><pub-id pub-id-type="pmcid">PMC7402632</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>M. W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nan</surname><given-names>M. L.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 ORF9b antagonizes type I and III interferons by targeting multiple components of the RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING signaling pathways.</article-title><source><italic toggle="yes">J. Med. Virol.</italic></source><volume>93</volume><fpage>5376</fpage>&#8211;<lpage>5389</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.27050</pub-id><pub-id pub-id-type="pmid">33913550</pub-id><pub-id pub-id-type="pmcid">PMC8242602</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hedayat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Rezaei</surname><given-names>N.</given-names></name></person-group> (<year>2011</year>). <article-title>Targeting of Toll-like receptors: a decade of progress in combating infectious diseases.</article-title><source><italic toggle="yes">Lancet Infect. Dis.</italic></source><volume>11</volume><fpage>702</fpage>&#8211;<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1016/s1473-3099(11)70099-8</pub-id><pub-id pub-id-type="pmid">21719349</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heitmann</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Bilich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tandler</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nelde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maringer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Marconato</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity.</article-title><source><italic toggle="yes">Nature</italic></source><volume>601</volume><fpage>617</fpage>&#8211;<lpage>622</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-021-04232-5</pub-id><pub-id pub-id-type="pmid">34814158</pub-id><pub-id pub-id-type="pmcid">PMC8791831</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>Y. K.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>J. H.</given-names></name><name name-style="western"><surname>Ham</surname><given-names>S. J.</given-names></name><name name-style="western"><surname>Yum</surname><given-names>J. S.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>B. C.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity.</article-title><source><italic toggle="yes">Vaccines</italic></source><volume>9</volume>:<fpage>957</fpage>.<pub-id pub-id-type="pmid">34579194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9090957</pub-id><pub-id pub-id-type="pmcid">PMC8473206</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>H. W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H. N.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Q. F.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70.</article-title><source><italic toggle="yes">Cell. Mol. Immunol.</italic></source><volume>17</volume><fpage>998</fpage>&#8211;<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1038/s41423-020-0514-8</pub-id><pub-id pub-id-type="pmid">32728199</pub-id><pub-id pub-id-type="pmcid">PMC7387808</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>H. E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>13</volume>:<fpage>2132</fpage>. <pub-id pub-id-type="doi">10.3390/v13112132</pub-id><pub-id pub-id-type="pmid">34834939</pub-id><pub-id pub-id-type="pmcid">PMC8622567</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kate Gadanec</surname><given-names>L.</given-names></name><name name-style="western"><surname>Qaradakhi</surname><given-names>T.</given-names></name><name name-style="western"><surname>McSweeney</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ashiana Ali</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zulli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Apostolopoulos</surname><given-names>V.</given-names></name></person-group> (<year>2021</year>). <article-title>Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.</article-title><source><italic toggle="yes">Future Microbiol.</italic></source><volume>16</volume><fpage>205</fpage>&#8211;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.2217/fmb-2021-0018</pub-id><pub-id pub-id-type="pmid">33569984</pub-id><pub-id pub-id-type="pmcid">PMC7885526</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group> (<year>2011</year>). <article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.</article-title><source><italic toggle="yes">Immunity</italic></source><volume>34</volume><fpage>637</fpage>&#8211;<lpage>650</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><pub-id pub-id-type="pmid">21616434</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawasaki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name></person-group> (<year>2014</year>). <article-title>Toll-like receptor signaling pathways.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>5</volume>:<fpage>461</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00461</pub-id><pub-id pub-id-type="pmid">25309543</pub-id><pub-id pub-id-type="pmcid">PMC4174766</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kayesh</surname><given-names>M. E. H.</given-names></name><name name-style="western"><surname>Kohara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsukiyama-Kohara</surname><given-names>K.</given-names></name></person-group> (<year>2021</year>). <article-title>An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.</article-title><source><italic toggle="yes">Viruses</italic></source><volume>13</volume>:<fpage>2302</fpage>. <pub-id pub-id-type="doi">10.3390/v13112302</pub-id><pub-id pub-id-type="pmid">34835108</pub-id><pub-id pub-id-type="pmcid">PMC8622245</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khadke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ratts</surname><given-names>R.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gallogly</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.</article-title><source><italic toggle="yes">Virol. J.</italic></source><volume>17</volume>:<fpage>154</fpage>. <pub-id pub-id-type="doi">10.1186/s12985-020-01415-w</pub-id><pub-id pub-id-type="pmid">33059711</pub-id><pub-id pub-id-type="pmcid">PMC7558250</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khalifa</surname><given-names>A. E.</given-names></name><name name-style="western"><surname>Ghoneim</surname><given-names>A. I.</given-names></name></person-group> (<year>2021</year>). <article-title>Potential value of pharmacological agents acting on toll-like receptor (TLR) 7 and/or TLR8 in COVID-19.</article-title><source><italic toggle="yes">Curr. Res. Pharmacol. Drug Discov.</italic></source><volume>2</volume>:<fpage>100068</fpage>. <pub-id pub-id-type="doi">10.1016/j.crphar.2021.100068</pub-id><pub-id pub-id-type="pmid">34870161</pub-id><pub-id pub-id-type="pmcid">PMC8562070</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shafiei</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Longoria</surname><given-names>C.</given-names></name><name name-style="western"><surname>Schoggins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Savani</surname><given-names>R. C.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>H.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#954;B pathway.</article-title><source><italic toggle="yes">bioRxiv</italic></source> [<comment>Preprint</comment>]. <pub-id pub-id-type="doi">10.1101/2021.03.16.435700</pub-id>. <pub-id pub-id-type="pmid">34866574</pub-id><pub-id pub-id-type="pmcid">PMC8709575</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shereen</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Emergence of a Novel Coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2: biology and Therapeutic Options.</article-title><source><italic toggle="yes">J. Clin. Microbiol.</italic></source><volume>58</volume>:<fpage>e00187</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/jcm.00187-20</pub-id><pub-id pub-id-type="pmid">32161092</pub-id><pub-id pub-id-type="pmcid">PMC7180238</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>A. Y.</given-names></name><name name-style="western"><surname>Shim</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Heo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Youn</surname><given-names>H. S.</given-names></name></person-group> (<year>2018</year>). <article-title>Differential regulation of MyD88- and TRIF-dependent signaling pathways of Toll-like receptors by cardamonin.</article-title><source><italic toggle="yes">Int. Immunopharmacol.</italic></source><volume>64</volume><fpage>1</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2018.08.018</pub-id><pub-id pub-id-type="pmid">30142469</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Konno</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kimura</surname><given-names>I.</given-names></name><name name-style="western"><surname>Uriu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fukushi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Irie</surname><given-names>T.</given-names></name><name name-style="western"><surname>Koyanagi</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant.</article-title><source><italic toggle="yes">Cell Rep.</italic></source><volume>32</volume>:<fpage>108185</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.108185</pub-id><pub-id pub-id-type="pmid">32941788</pub-id><pub-id pub-id-type="pmcid">PMC7473339</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langellotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dellacherie</surname><given-names>M. O.</given-names></name><name name-style="western"><surname>Yeager</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ijaz</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>C. A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>A Modular Biomaterial Scaffold-Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARS-CoV-2 Antigens.</article-title><source><italic toggle="yes">Adv. Healthc. Mater.</italic></source><volume>10</volume>:<fpage>e210137</fpage>. <pub-id pub-id-type="doi">10.1002/adhm.202101370</pub-id><pub-id pub-id-type="pmid">34605223</pub-id><pub-id pub-id-type="pmcid">PMC8652677</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Activation and evasion of type I interferon responses by SARS-CoV-2.</article-title><source><italic toggle="yes">Nat. Commun.</italic></source><volume>11</volume>:<fpage>3810</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-020-17665-9</pub-id><pub-id pub-id-type="pmid">32733001</pub-id><pub-id pub-id-type="pmcid">PMC7392898</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lester</surname><given-names>S. N.</given-names></name><name name-style="western"><surname>Li</surname><given-names>K.</given-names></name></person-group> (<year>2014</year>). <article-title>Toll-like receptors in antiviral innate immunity.</article-title><source><italic toggle="yes">J. Mol. Biol.</italic></source><volume>426</volume><fpage>1246</fpage>&#8211;<lpage>1264</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2013.11.024</pub-id><pub-id pub-id-type="pmid">24316048</pub-id><pub-id pub-id-type="pmcid">PMC3943763</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Jing</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>Adjuvants for Coronavirus Vaccines.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>11</volume>:<fpage>589833</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.589833</pub-id><pub-id pub-id-type="pmid">33240278</pub-id><pub-id pub-id-type="pmcid">PMC7677582</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>C.</given-names></name><name name-style="western"><surname>An</surname><given-names>J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants.</article-title><source><italic toggle="yes">Vaccine</italic></source><volume>39</volume><fpage>7001</fpage>&#8211;<lpage>7011</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.10.066</pub-id><pub-id pub-id-type="pmid">34750014</pub-id><pub-id pub-id-type="pmcid">PMC8556577</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Fast and long-lasting immune response to S-trimer COVID-19 vaccine adjuvanted by PIKA.</article-title><source><italic toggle="yes">Mol. Biomed.</italic></source><volume>2</volume>:<fpage>29</fpage>. <pub-id pub-id-type="doi">10.1186/s43556-021-00054-z</pub-id><pub-id pub-id-type="pmid">34766005</pub-id><pub-id pub-id-type="pmcid">PMC8475395</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>R. K.</given-names></name></person-group> (<year>2021</year>). <article-title>Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19.</article-title><source><italic toggle="yes">J. Med. Virol.</italic></source><volume>94</volume><fpage>869</fpage>&#8211;<lpage>877</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.27405</pub-id><pub-id pub-id-type="pmid">34672376</pub-id><pub-id pub-id-type="pmcid">PMC8662021</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mellett</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khader</surname><given-names>S. A.</given-names></name></person-group> (<year>2022</year>). <article-title>S100A8/A9 in COVID-19 pathogenesis: impact on clinical outcomes.</article-title><source><italic toggle="yes">Cytokine Growth Factor Rev.</italic></source><volume>63</volume><fpage>90</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.cytogfr.2021.10.004</pub-id><pub-id pub-id-type="pmid">34728150</pub-id><pub-id pub-id-type="pmcid">PMC8520505</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mohanty</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Varose</surname><given-names>S. Y.</given-names></name><name name-style="western"><surname>Sawant</surname><given-names>U. P.</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>M. M.</given-names></name></person-group> (<year>2021</year>). <article-title>Expression of innate immune response genes in upper airway samples of SARS-CoV-2 infected patients: a preliminary study.</article-title><source><italic toggle="yes">Indian J. Med. Res.</italic></source><volume>153</volume><fpage>677</fpage>&#8211;<lpage>683</lpage>. <pub-id pub-id-type="doi">10.4103/ijmr.IJMR_131_21</pub-id><pub-id pub-id-type="pmid">34528526</pub-id><pub-id pub-id-type="pmcid">PMC8555587</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mukherjee</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bojkova</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mehdipour</surname><given-names>A. R.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>K. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection.</article-title><source><italic toggle="yes">J. Biol. Chem.</italic></source><volume>297</volume>:<fpage>100925</fpage>. <pub-id pub-id-type="doi">10.1016/j.jbc.2021.100925</pub-id><pub-id pub-id-type="pmid">34214498</pub-id><pub-id pub-id-type="pmcid">PMC8241579</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohto</surname><given-names>U.</given-names></name><name name-style="western"><surname>Ishida</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name></person-group> (<year>2018</year>). <article-title>Toll-like Receptor 9 Contains Two DNA Binding Sites that Function Cooperatively to Promote Receptor Dimerization and Activation.</article-title><source><italic toggle="yes">Immunity</italic></source><volume>48</volume><fpage>649</fpage>&#8211;<lpage>658.e4</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.013</pub-id><pub-id pub-id-type="pmid">29625894</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oldenburg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kr&#252;ger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferstl</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kaufmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nees</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sigmund</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>TLR13 recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming modification.</article-title><source><italic toggle="yes">Science</italic></source><volume>337</volume><fpage>1111</fpage>&#8211;<lpage>1115</lpage>. <pub-id pub-id-type="doi">10.1126/science.1220363</pub-id><pub-id pub-id-type="pmid">22821982</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group> (<year>2020</year>). <article-title>Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.</article-title><source><italic toggle="yes">Cell Host Microbe.</italic></source><volume>27</volume><fpage>870</fpage>&#8211;<lpage>878</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2020.05.008</pub-id><pub-id pub-id-type="pmid">32464097</pub-id><pub-id pub-id-type="pmcid">PMC7255347</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patidar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selvaraj</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sarode</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chauhan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chattopadhyay</surname><given-names>D.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>B.</given-names></name></person-group> (<year>2018</year>). <article-title>DAMP-TLR-cytokine axis dictates the fate of tumor.</article-title><source><italic toggle="yes">Cytokine</italic></source><volume>104</volume><fpage>114</fpage>&#8211;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2017.10.004</pub-id><pub-id pub-id-type="pmid">29032985</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chandra Das</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>Targeting human TLRs to combat COVID-19: a solution?</article-title><source><italic toggle="yes">J. Med. Virol.</italic></source><volume>93</volume><fpage>615</fpage>&#8211;<lpage>617</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.26387</pub-id><pub-id pub-id-type="pmid">32749702</pub-id><pub-id pub-id-type="pmcid">PMC7436140</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Port</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>J. V.</given-names></name><name name-style="western"><surname>Klopp-Schulze</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bytyqi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vetter</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.</article-title><source><italic toggle="yes">Pharmacol. Res. Perspect.</italic></source><volume>9</volume>:<fpage>e00842</fpage>. <pub-id pub-id-type="doi">10.1002/prp2.842</pub-id><pub-id pub-id-type="pmid">34414672</pub-id><pub-id pub-id-type="pmcid">PMC8377444</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qian</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>T.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P. S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C. H.</given-names></name><name name-style="western"><surname>Monaghan-Nichols</surname><given-names>P.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>H. B.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.</article-title><source><italic toggle="yes">J. Virol.</italic></source><volume>95</volume>:<fpage>e0139621</fpage>. <pub-id pub-id-type="doi">10.1128/JVI.01396-21</pub-id><pub-id pub-id-type="pmid">34549987</pub-id><pub-id pub-id-type="pmcid">PMC8577385</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rammensee</surname><given-names>H. G.</given-names></name><name name-style="western"><surname>Gouttefangeas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Heidu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klein</surname><given-names>R.</given-names></name><name name-style="western"><surname>Preuss</surname><given-names>B.</given-names></name><name name-style="western"><surname>Walz</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups.</article-title><source><italic toggle="yes">Vaccines</italic></source><volume>9</volume>:<fpage>428</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9050428</pub-id><pub-id pub-id-type="pmid">33923363</pub-id><pub-id pub-id-type="pmcid">PMC8146137</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Richmond</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hatchuel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.</article-title><source><italic toggle="yes">Lancet</italic></source><volume>397</volume><fpage>682</fpage>&#8211;<lpage>694</lpage>. <pub-id pub-id-type="doi">10.1016/s0140-6736(21)00241-5</pub-id><pub-id pub-id-type="pmid">33524311</pub-id><pub-id pub-id-type="pmcid">PMC7906655</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossmann</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bagola</surname><given-names>K.</given-names></name><name name-style="western"><surname>Stephen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gerards</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Walber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ullrich</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response.</article-title><source><italic toggle="yes">Proc. Natl. Acad. Sci. U.S..A.</italic></source><volume>118</volume>:<fpage>e2103651118</fpage>. <pub-id pub-id-type="doi">10.1073/pnas.2103651118</pub-id><pub-id pub-id-type="pmid">34561306</pub-id><pub-id pub-id-type="pmcid">PMC8488681</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salvi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>H. O.</given-names></name><name name-style="western"><surname>Sozio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Schioppa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gaudenzi</surname><given-names>C.</given-names></name><name name-style="western"><surname>Laffranchi</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2-associated ssRNAs activate inflammation and immunity via TLR7/8.</article-title><source><italic toggle="yes">JCI Insight</italic></source><volume>6</volume>:<fpage>e150542</fpage>.<pub-id pub-id-type="pmid">34375313</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/jci.insight.150542</pub-id><pub-id pub-id-type="pmcid">PMC8492321</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sariol</surname><given-names>A.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 takes its Toll.</article-title><source><italic toggle="yes">Nat. Immunol.</italic></source><volume>22</volume><fpage>801</fpage>&#8211;<lpage>802</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-00962-w</pub-id><pub-id pub-id-type="pmid">34103714</pub-id><pub-id pub-id-type="pmcid">PMC8238877</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schlee</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>G.</given-names></name></person-group> (<year>2016</year>). <article-title>Discriminating self from non-self in nucleic acid sensing.</article-title><source><italic toggle="yes">Nat Rev. Immunol.</italic></source><volume>16</volume><fpage>566</fpage>&#8211;<lpage>580</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.78</pub-id><pub-id pub-id-type="pmid">27455396</pub-id><pub-id pub-id-type="pmcid">PMC7097691</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kizaki</surname><given-names>T.</given-names></name></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 spike protein S1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages.</article-title><source><italic toggle="yes">Heliyon</italic></source><volume>7</volume>:<fpage>e06187</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2021.e06187</pub-id><pub-id pub-id-type="pmid">33644468</pub-id><pub-id pub-id-type="pmcid">PMC7887388</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohn</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S. G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H. J.</given-names></name><name name-style="western"><surname>Cheon</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jeong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis.</article-title><source><italic toggle="yes">J. Korean Med. Sci.</italic></source><volume>35</volume>:<fpage>e343</fpage>. <pub-id pub-id-type="doi">10.3346/jkms.2020.35.e343</pub-id><pub-id pub-id-type="pmid">32989935</pub-id><pub-id pub-id-type="pmcid">PMC7521960</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mifune</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morin</surname><given-names>M. D.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>B. T.</given-names></name><etal/></person-group> (<year>2019</year>). <article-title>Structural Basis of TLR2/TLR1 Activation by the Synthetic Agonist Diprovocim.</article-title><source><italic toggle="yes">J. Med. Chem.</italic></source><volume>62</volume><fpage>2938</fpage>&#8211;<lpage>2949</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b01583</pub-id><pub-id pub-id-type="pmid">30829478</pub-id><pub-id pub-id-type="pmcid">PMC6537610</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 Membrane Protein Inhibits Type I Interferon Production Through Ubiquitin-Mediated Degradation of TBK1.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>12</volume>:<fpage>662989</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2021.662989</pub-id><pub-id pub-id-type="pmid">34084167</pub-id><pub-id pub-id-type="pmcid">PMC8168463</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sui</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>S. K.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Venzon</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Protection against SARS-CoV-2 infection by a mucosal vaccine in rhesus macaques.</article-title><source><italic toggle="yes">JCI Insight</italic></source><volume>6</volume>:<fpage>e148494</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.148494</pub-id><pub-id pub-id-type="pmid">33908897</pub-id><pub-id pub-id-type="pmcid">PMC8262352</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tabary</surname><given-names>M.</given-names></name><name name-style="western"><surname>Khanmohammadi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Araghi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Dadkhahfar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tavangar</surname><given-names>S. M.</given-names></name></person-group> (<year>2020</year>). <article-title>Pathologic features of COVID-19: a concise review.</article-title><source><italic toggle="yes">Pathol. Res. Pract.</italic></source><volume>216</volume>:<fpage>153097</fpage>. <pub-id pub-id-type="doi">10.1016/j.prp.2020.153097</pub-id><pub-id pub-id-type="pmid">32825963</pub-id><pub-id pub-id-type="pmcid">PMC7334952</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>C.</given-names></name></person-group> (<year>2020</year>). <article-title>Cytokine Storm in COVID-19: the Current Evidence and Treatment Strategies.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>11</volume>:<fpage>1708</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2020.01708</pub-id><pub-id pub-id-type="pmid">32754163</pub-id><pub-id pub-id-type="pmcid">PMC7365923</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tanji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ohto</surname><given-names>U.</given-names></name><name name-style="western"><surname>Shibata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Miyake</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>T.</given-names></name></person-group> (<year>2013</year>). <article-title>Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands.</article-title><source><italic toggle="yes">Science</italic></source><volume>339</volume><fpage>1426</fpage>&#8211;<lpage>1429</lpage>. <pub-id pub-id-type="doi">10.1126/science.1229159</pub-id><pub-id pub-id-type="pmid">23520111</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiboni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Casettari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Illum</surname><given-names>L.</given-names></name></person-group> (<year>2021</year>). <article-title>Nasal vaccination against SARS-CoV-2: synergistic or alternative to intramuscular vaccines?</article-title><source><italic toggle="yes">Int. J. Pharm.</italic></source><volume>603</volume>:<fpage>120686</fpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120686</pub-id><pub-id pub-id-type="pmid">33964339</pub-id><pub-id pub-id-type="pmcid">PMC8099545</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Totura</surname><given-names>A. L.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schafer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Katze</surname><given-names>M. G.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M. T.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.</article-title><source><italic toggle="yes">mBio</italic></source><volume>6</volume>:<fpage>e00638-15</fpage>. <pub-id pub-id-type="doi">10.1128/mBio.00638-15</pub-id><pub-id pub-id-type="pmid">26015500</pub-id><pub-id pub-id-type="pmcid">PMC4447251</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turton</surname><given-names>H. A.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A. A. R.</given-names></name><name name-style="western"><surname>Farkas</surname><given-names>L.</given-names></name></person-group> (<year>2020</year>). <article-title>RNA Signaling in Pulmonary Arterial Hypertension-A Double-Stranded Sword.</article-title><source><italic toggle="yes">Int. J. Mol. Sci.</italic></source><volume>21</volume>:<fpage>3124</fpage>. <pub-id pub-id-type="doi">10.3390/ijms21093124</pub-id><pub-id pub-id-type="pmid">32354189</pub-id><pub-id pub-id-type="pmcid">PMC7247700</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vaure</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group> (<year>2014</year>). <article-title>A comparative review of toll-like receptor 4 expression and functionality in different animal species.</article-title><source><italic toggle="yes">Front. Immunol.</italic></source><volume>5</volume>:<fpage>316</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00316</pub-id><pub-id pub-id-type="pmid">25071777</pub-id><pub-id pub-id-type="pmcid">PMC4090903</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Veras</surname><given-names>F. P.</given-names></name><name name-style="western"><surname>Pontelli</surname><given-names>M. C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>C. M.</given-names></name><name name-style="western"><surname>Toller-Kawahisa</surname><given-names>J. E.</given-names></name><name name-style="western"><surname>de Lima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>D. C.</given-names></name><etal/></person-group> (<year>2020</year>). <article-title>SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology.</article-title><source><italic toggle="yes">J. Exp. Med.</italic></source><volume>217</volume>:<fpage>e20201129</fpage>. <pub-id pub-id-type="doi">10.1084/jem.20201129</pub-id><pub-id pub-id-type="pmid">32926098</pub-id><pub-id pub-id-type="pmcid">PMC7488868</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viveiros</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rasmuson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mulvagh</surname><given-names>S. L.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>C. Y. Y.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>C. M.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones.</article-title><source><italic toggle="yes">Am. J. Physiol. Heart Circ. Physiol.</italic></source><volume>320</volume><fpage>H296</fpage>&#8211;<lpage>H304</lpage>. <pub-id pub-id-type="doi">10.1152/ajpheart.00755.2020</pub-id><pub-id pub-id-type="pmid">33275517</pub-id><pub-id pub-id-type="pmcid">PMC8083171</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group> (<year>2016</year>). <article-title>Structure of the mouse Toll-like receptor 13 ectodomain in complex with a conserved sequence from bacterial 23S ribosomal RNA.</article-title><source><italic toggle="yes">FEBS J.</italic></source><volume>283</volume><fpage>1631</fpage>&#8211;<lpage>1635</lpage>. <pub-id pub-id-type="doi">10.1111/febs.13628</pub-id><pub-id pub-id-type="pmid">26676765</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>X. G.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R. Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2022</year>). <article-title>MPLA-Adjuvanted Liposomes Encapsulating S-Trimer or RBD or S1, but Not S-ECD, Elicit Robust Neutralization Against SARS-CoV-2 and Variants of Concern.</article-title><source><italic toggle="yes">J. Med. Chem.</italic></source><volume>65</volume><fpage>3563</fpage>&#8211;<lpage>3574</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02025</pub-id><pub-id pub-id-type="pmid">35108485</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Systemic antiviral immunization by virus-mimicking nanoparticles-decorated erythrocytes.</article-title><source><italic toggle="yes">Nano Today</italic></source><volume>40</volume>:<fpage>101280</fpage>. <pub-id pub-id-type="doi">10.1016/j.nantod.2021.101280</pub-id><pub-id pub-id-type="pmid">34512795</pub-id><pub-id pub-id-type="pmcid">PMC8418322</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>C. A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y. L.</given-names></name><name name-style="western"><surname>Chiang</surname><given-names>B. L.</given-names></name></person-group> (<year>2022</year>). <article-title>Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictors.</article-title><source><italic toggle="yes">J. Formos Med. Assoc.</italic></source><volume>121</volume><fpage>623</fpage>&#8211;<lpage>632</lpage>. <pub-id pub-id-type="doi">10.1016/j.jfma.2021.06.009</pub-id><pub-id pub-id-type="pmid">34193364</pub-id><pub-id pub-id-type="pmcid">PMC8214167</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ju</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ragab</surname><given-names>A. A.</given-names></name><name name-style="western"><surname>Lundback</surname><given-names>P.</given-names></name><name name-style="western"><surname>Long</surname><given-names>W.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>MD-2 is required for disulfide HMGB1-dependent TLR4 signaling.</article-title><source><italic toggle="yes">J. Exp. Med.</italic></source><volume>212</volume><fpage>5</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20141318</pub-id><pub-id pub-id-type="pmid">25559892</pub-id><pub-id pub-id-type="pmcid">PMC4291531</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name></person-group> (<year>2017</year>). <article-title>TLR5: beyond the recognition of flagellin.</article-title><source><italic toggle="yes">Cell Mol. Immunol.</italic></source><volume>14</volume><fpage>1017</fpage>&#8211;<lpage>1019</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2017.122</pub-id><pub-id pub-id-type="pmid">29151579</pub-id><pub-id pub-id-type="pmcid">PMC5719140</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yokota</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okabayashi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>N.</given-names></name></person-group> (<year>2010</year>). <article-title>The battle between virus and host: modulation of Toll-like receptor signaling pathways by virus infection.</article-title><source><italic toggle="yes">Mediators Inflamm.</italic></source><volume>2010</volume>:<fpage>184328</fpage>. <pub-id pub-id-type="doi">10.1155/2010/184328</pub-id><pub-id pub-id-type="pmid">20672047</pub-id><pub-id pub-id-type="pmcid">PMC2903949</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></name></person-group> (<year>2018</year>). <article-title>The Role of Toll-Like Receptor Signaling in the Progression of Heart Failure.</article-title><source><italic toggle="yes">Mediators Inflamm.</italic></source><volume>2018</volume>:<fpage>9874109</fpage>. <pub-id pub-id-type="doi">10.1155/2018/9874109</pub-id><pub-id pub-id-type="pmid">29576748</pub-id><pub-id pub-id-type="pmcid">PMC5822798</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus.</article-title><source><italic toggle="yes">Cell. Mol. Immunol.</italic></source><volume>13</volume><fpage>180</fpage>&#8211;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Huo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy.</article-title><source><italic toggle="yes">Signal Transduct. Target. Ther.</italic></source><volume>6</volume>:<fpage>233</fpage>. <pub-id pub-id-type="doi">10.1038/s41392-021-00653-w</pub-id><pub-id pub-id-type="pmid">34117216</pub-id><pub-id pub-id-type="pmcid">PMC8193598</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>SARS-CoV-2 spike protein interacts with and activates TLR41.</article-title><source><italic toggle="yes">Cell Res.</italic></source><volume>31</volume><fpage>818</fpage>&#8211;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-021-00495-9</pub-id><pub-id pub-id-type="pmid">33742149</pub-id><pub-id pub-id-type="pmcid">PMC7975240</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karki</surname><given-names>R.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>E. P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fitzpatrick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P.</given-names></name><etal/></person-group> (<year>2021</year>). <article-title>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines.</article-title><source><italic toggle="yes">Nat. Immunol.</italic></source><volume>22</volume><fpage>829</fpage>&#8211;<lpage>838</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id><pub-id pub-id-type="pmid">33963333</pub-id><pub-id pub-id-type="pmcid">PMC8882317</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>